"Over the years, novel therapeutics developed at Genentech have extended patients’ life span and improved their quality of life. It’s incredibly rewarding to be a part of it. I am energized everyday to be working alongside so many talented scientists that are dedicated to bringing safe and efficacious drugs to patients."
I joined Genentech in 2006 as a Scientist in the Safety Assessment Department. I’ve had the opportunity to design and lead the nonclinical safety strategies of many programs spanning from early discovery to post-marketing, and on a diverse platform of molecules including therapeutic antibodies, antibody-drug conjugates, and small molecules. Our study results are used to support clinical development and registration of these novel therapeutics. Our science-based, innovative approaches have enabled us to continue to bring novel drugs forward and advance the science of preclinical safety evaluation. Currently I am responsible for overall preclinical safety strategy and deliverables of the oncology programs. I’ve also had the opportunities to lead Pharmacology Subteams where I am ultimately responsible for overall preclinical development strategies.
I received MD in 1990 and PhD in 1997. I found my passion in drug development and translational safety evaluation, and have worked in biotechnology and pharmaceutical companies for almost 18 years.
Toxicol Pathol. 2012;40(2):272-87.